Table 1.
Sample information of the included individuals and type of analysis performed on the serum.
| Sample information | Analysis | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group ID | # | Sample ID | Sample year | Sex | Year of birth | Age [years] | Anti-PTx IgG [IU/ml] | Vaccination scheme (months/years) | Years since vaccination | MIA | SDS-PAGE | 2DEWB | |||
| IgG | IgA | IgG | IgA | IgG | IgA | ||||||||||
| 1 | SSI-05 | 2016 | Female | 1999 | 16 | 6 | 3, 5, 12 m + 5 y | 12 | X | X | X | X | X | ||
| 2 | SSI-08 | 2016 | Male | 1998 | 17 | 6 | 3, 5, 12 m + 5 y | 11 | X | X | X | X | |||
| 3 | SSI-25 | 2016 | Female | 1999 | 17 | 4 | 3, 5, 12 m + 5 y | 12 | X | X | X | X | |||
| 4 | SSI-26 | 2016 | Female | 1999 | 16 | 12 | 3, 5, 12 m + 5 y | 11 | X | X | X | X | X | ||
| aPV low anti-PTx (aPV-) | 5 | SSI-27 | 2015 | Female | 1998 | 17 | 13 | 3, 5, 12 m + 5 y | 12 | X | X | X | X | ||
| 6 | SSI-28 | 2015 | Female | 1999 | 15 | 8 | 3, 5, 12 m + 5 y | 11 | X | X | X | X | X | ||
| 7 | SSI-29 | 2015 | Female | 1998 | 16 | 9 | 3, 5, 12 m + 5 y | 12 | X | X | X | X | X | ||
| 8 | SSI-34 | 2015 | Female | 2000 | 15 | 3 | 3, 5, 12 m + 5 y | 10 | X | X | X | X | X | X | |
| 9 | SSI-35 | 2016 | Female | 2000 | 15 | 15 | 3, 5, 12 m + 5 y | 10 | X | X | X | X | |||
| Mean ± Stdev | 16.0 ± 0.8 | ||||||||||||||
| 10 | SSI-03 | 2016 | Female | 1994 | 21 | 3 | X | X | X | X | X | X | |||
| 11 | SSI-04 | 2016 | Male | 1994 | 22 | 3 | X | X | X | X | |||||
| 12 | SSI-13 | 2016 | Female | 1995 | 21 | 12 | X | X | X | X | |||||
| 13 | SSI-14 | 2016 | Female | 1995 | 20 | 3 | X | X | X | X | |||||
| wPV low anti-PTx (wPV-) | 14 | SSI-15 | 2015 | Female | 1995 | 20 | 14 | X | X | X | X | ||||
| 15 | SSI-16 | 2015 | Male | 1995 | 20 | 14 | X | X | X | X | X | ||||
| 16 | SSI-17 | 2015 | Female | 1995 | 20 | 9 | X | X | X | X | X | X | |||
| 17 | SSI-18 | 2015 | Female | 1995 | 20 | 9 | X | X | X | X | X | ||||
| 18 | SSI-19 | 2015 | Male | 1995 | 20 | 4 | X | X | X | X | |||||
| Mean ± Stdev | 20.4 ± 0.7 | ||||||||||||||
| 19 | SSI-02 | 2016 | Male | 1999 | 16 | ≥260 | 3, 5, 12 m + 5 y | 11 | X | X | X | X | X | X | |
| 20 | SSI-06 | 2015 | Male | 1999 | 15 | 203 | 3, 5, 12 m + 5 y | 10 | X | X | X | X | X | X | |
| 21 | SSI-20 | 2016 | Female | 1999 | 17 | ≥260 | 3, 5, 12 m + 5 y | 12 | X | X | X | X | |||
| 22 | SSI-21 | 2016 | Female | 1999 | 16 | 229 | 3, 5, 12 m + 5 y | 12 | X | X | X | X | |||
| aPV high anti-PTx (aPV+) | 23 | SSI-22 | 2015 | Male | 1999 | 15 | ≥260 | 3, 5, 12 m + 5 y | 11 | X | X | X | X | ||
| 24 | SSI-23 | 2015 | Female | 1999 | 16 | ≥260 | 3, 5, 12 m + 5 y | 11 | X | X | X | X | |||
| 25 | SSI-24 | 2015 | Male | 1999 | 15 | ≥260 | 3, 5, 12 m + 5 y | 10 | X | X | X | X | X | ||
| 26 | SSI-32 | 2014 | Female | 1999 | 14 | 182 | 3, 5, 12 m + 5 y | 10 | X | X | X | X | X | ||
| 27 | SSI-33 | 2014 | Female | 1998 | 15 | ≥260 | 3, 5, 12 m + 5 y | 11 | X | X | X | X | |||
| Mean ± Stdev | 15.4 ± 0.8 | ||||||||||||||
| 28 | SSI-01 | 2015 | Male | 1995 | 19 | ≥260 | X | X | X | X | X | ||||
| 29 | SSI-07 | 2015 | Male | 1995 | 20 | 151 | X | X | X | X | X | X | |||
| 30 | SSI-09 | 2016 | Female | 1995 | 21 | 196 | X | X | X | X | |||||
| 31 | SSI-10 | 2016 | Female | 1995 | 20 | ≥260 | X | X | X | X | X | ||||
| wPV high anti-PTx (wPV+) | 32 | SSI-11 | 2016 | Female | 1995 | 20 | 187 | X | X | X | X | ||||
| 33 | SSI-12 | 2016 | Female | 1995 | 20 | ≥260 | X | X | X | X | |||||
| 34 | SSI-30 | 2014 | Male | 1994 | 19 | ≥260 | X | X | X | X | |||||
| 35 | SSI-31 | 2014 | Male | 1995 | 19 | ≥260 | X | X | X | X | X | ||||
| 36 | SSI-36 | 2016 | Male | 1994 | 21 | ≥260 | X | X | X | X | X | ||||
| Mean ± Stdev | 19.9 ± 0.7 | ||||||||||||||